Navigation Links
Frost & Sullivan Recognizes ApaTech's Leadership in Orthopedic Biologics

MOUNTAIN VIEW, Calif., March 19 /PRNewswire/ -- Based on its recent analysis of the device biologics market, Frost & Sullivan recognizes ApaTech with the 2009 North American Frost & Sullivan Company of the Year Award. The device biologics market is one of the most lucrative in the medical device industry. Though relatively new, the field has already experienced periods of breakthrough innovation as evidenced in ApaTech's products.


Cutting edge research by ApaTech has introduced the revolutionary new class of bone graft substitute called Actifuse, which is based on silicated calcium phosphate. This development is a definitive factor in the growth and success of this company, which is driven by a commitment to the progress of orthopedic biologics. ApaTech has achieved this through clear product differentiation strategies and sound marketing tactics, addressing key market issues.

"ApaTech is set to build on a very strong base it has established in the advanced geographies, and as cash-rich medical markets increase, revenue growth and consolidation of market share are inevitable," says Frost & Sullivan Industry Analyst, Aarti Shetty.

Traditional autogenous grafts, or autografts, were widely considered the "gold standard" among bone graft materials. Despite the material being transplanted from the same individual, complications and pain at the affected site have been common. The clinical effectiveness of autografts is considered the primary reason for their wide acceptance. But improved synthetic materials treated with sophisticated methods for increasing biological activity, have the added advantage of avoiding a secondary procedure, and considerably eliminating the risks involved with surgery. In particular calcium phosphates have emerged as the alternative of choice, due to their ability to closely mimic bone characteristics in terms of chemical nature and structural stability.

ApaTech's Actifuse is a new class of synthetic bone graft and is an exceptional bone graft material. Silicate ions are used to selectively replace phosphate groups in the calcium phosphate crystal lattice. This new material accelerates the formation of bone. The resultant bone composite structure contains greater amount of natural bone as compared to traditional synthetic graft material. The silicate substituted calcium phosphate material also displays excellent porosity at all levels, allowing for natural networking of capillaries and bone matter during formation. Actifuse combines osteoconductive and osteo-stimulatory activities, making it suitable for a wide range of orthopedic and spinal applications.

"Improvements in clinical outcomes and patient comfort after Actifuse-based procedures have boosted its reputation considerably, and the technology is used globally for spinal fusions, joint reconstruction, trauma and voids induced by bone tumors," notes Shetty. "ApaTech's first bone graft substitute ApaPore has also been a successful offering, available in a range of porosities each customized according to individual surgical applications and the company is building on its successes through relentless study of improved materials and techniques."

For instance, complex anatomy has sometimes required bone graft materials to be formable, while retaining their core regenerative characteristics. Actifuse Shape is the first product to deliver on this expectation. Launched this year, Actifuse Shape, this formable out of the box fresh solution for bone grafting, was co-developed with Ceremed Inc. It merges the properties of Ceremed's AOC(TM) Biosoluble(TM) Copolymers with Actifuse to create a highly saleable range of products, which lend themselves to easy molding and/or cutting to the contours of the required grafting site. Another product that deserves recognition is Actifuse MIS, an extremely innovative delivery system that facilitates MIS procedures. Current bone grafting delivery methods available in the market fall short in providing the best ease-of-use in MIS procedures. ApaTech does well to satisfy this need, thus displaying its ability to listen to the needs of the market.

With sizeable increases in sales due to increased product acceptance, ApaTech is one of the fastest growing private companies in the UK today, selling its products in 22 major markets around the world. Several line extensions are in development or awaiting regulatory approval, all of which are suitably enhanced to meet demanding surgeon expectations. Due to its roots in academia, the company retains collaborations with research institutes with a view to develop more improved, biologically active synthetic bone grafts, to increase weight-bearing capabilities and to synthesize extendable variants of composite materials.

Overall, Frost & Sullivan recognizes the outstanding qualities that separate ApaTech from competitors in its line of business, and from alternative surgical approaches - both old and new. For its great potential to be a world leader in this area, and as a business at the center of progressive research in the orthopedic biologics space, Frost & Sullivan bestows the 2009 Company of the year Award in the U.S. Device Biologics market on ApaTech.

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in terms of business development, competitive strategy, customer satisfaction, and leadership within a particular Frost & Sullivan Industry Research Group (IRG). This award recognizes outstanding management, consistent growth, and the ability to offer high quality products and/or services as well as have a positive social and economic impact on local and national communities. It also highlights exceptional customer service offerings and the expertise to take advantage of market changes by capturing and solidifying market presence, or executing innovative strategies within the existing competitive landscape.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About ApaTech

ApaTech specializes in producing synthetic bone repair material. It has operations in London, England, Foxborough, USA, and Berlin, Germany, and is a world leader in bone graft technologies, selling its products in 26 countries around the world.

The Company has developed a novel silicate substituted calcium phosphate bone graft material, Actifuse, which underpins the Company's leadership in applying the science of silicon to bone graft technologies. The Company believes that Actifuse is the first of a new class of synthetic bone graft materials that combine osteo-conductive and osteo-stimulatory activities that accelerate bone healing.

ApaTech is backed by international investors, 3i and Healthcor and was recognized as Britain's fastest growing medical technology company in both the 2008 and 2007 Sunday Times Fast Track 100 fastest growing private companies review.

More details can be found at

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit

    Jake Wengroff

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Transport Pharmaceuticals Receives Coveted Frost & Sullivan Technology Innovation Award
2. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation
3. Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy
4. Signalife Wins Second Frost & Sullivan Technology Award
5. AdvanDx Receives Frost & Sullivans Rapid In-Vitro Diagnostic Technology Innovation of the Year Award
6. Modigene Announces Closing of $12 Million Financing by Members of The Frost Group
7. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
8. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
9. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
10. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
11. Frost & Sullivan Recognizes Kionixs Dominance in the MEMS Accelerometers Market Through Product Line Strategy
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015 Celemics, a global ... into the North American market with the establishment of ... and Europe , has secured ... Target Enrichment methodology and sample preparation for DNA sequencing ... both hereditary and somatic genetic testing more accurately, quickly, ...
(Date:10/8/2015)...  The ALS Association, in partnership with Prize4Life, is ... revolutionize communication technology solutions for people living with ALS. ... (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that ... spinal cord. Eventually, people with ALS lose the ability ... to total paralysis and death within two to five ...
(Date:10/8/2015)... ... October 08, 2015 , ... ... an exclusive license agreement to develop and commercialize intellectual property rights belonging to ... agreement from February 2009, and affords exclusive worldwide rights to intellectual property based ...
(Date:10/7/2015)... Texas (PRWEB) , ... October 07, 2015 , ... ... Institute ( ) will present a public educational seminar on the latest ... Saturday, October 10th from 1:00 pm – 3:00 pm at the Hilton Dallas/Southlake ...
Breaking Biology Technology:
... Merrimack Pharmaceuticals today announced that it will present at the Jefferies 2010 Global Life Sciences Conference ... provide a company overview at 11:00am EDT , Wednesday, June 9, 2010 at ... , , ... , , , ...
... June 1 Diplomat Specialty Pharmacy, the ... launch of Navigator Health Services, an independent division of ... pharmacy industry. The announcement was made by Diplomat Specialty ... who says that Navigator Health Services was formed in ...
... Calif. , June 1 Epeius Biotechnologies Corporation ( ... "Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as ... the ASCO Annual Meeting on June 8, 2010 . The ... Stanford University Medical Center, Palo Alto CA. ...
Cached Biology Technology:
(Date:9/10/2015)... , Sept. 10, 2015 Pursuant ... Clinic Wellness to create an interactive, image-based health ... health and wellness kiosk.  The unique assessment quantifies ... a number that suggests an individual,s biological age ... values as measured by the kiosk. ...
(Date:9/8/2015)... , Sept. 8, 2015   TREW Marketing ... the new survey, Smart Marketing for Engineers TM ... 580 engineering professionals reveals insightful findings about engineers, preferences ... types of content engineers most value and trust, and ... Marketers targeting technical audiences grapple with how to ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 ... key concern for enterprises, banks, government organizations, telecommunications, ... and numeric keypads were previously being used to ... introduction of two-factor authentication, wherein individuals could gain ... two different components, such as hardware devices and ...
Breaking Biology News(10 mins):
... "We can make you and we can break you." If ... oxide would start something like that. But this song wouldn,t ... of Rice chemist James Tour demonstrates an environmentally friendly way ... version of single-atom-thick graphene expected to find use in all ...
... A novel approach detects genetically abnormal cells in the blood ... in tumor cells and increase in number with the severity ... The University of Texas MD Anderson Cancer Center report in ... patients in the study also had many times the number ...
... A University of Minnesota Medical School research team led ... a novel approach to ease the chronic and acute ... a mouse model of SCD, Gupta and University of ... that exhibited both musculoskeletal pain and temperature sensitivity, symptoms ...
Cached Biology News:
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
Application: For use as a carrier in nucleic acid purification and precipitation. Physical form: Solution in 10 mM Tris HCl, pH 7.4, 1 mM EDTA Concentration: 9-11 mg/mL Physical Form: buffered aqu...
... Note: Prepared by a modification of ... al., Biotechnol. Bioeng., 11 ... unit will yield an A 260 ... of water (1 cm light path). ...
... Unique, compact measuring instrument for calibrating ... compact design and the robust carrying case, ... both in the laboratory and on-site at ... easy to use because the individual channels ...
Biology Products: